ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 16.9 | 18.8 | 14.1 |
| Other income | 0.4 | 0.0 | 0.1 |
| Total income | 17.2 | 18.8 | 14.1 |
| Profit before exceptional items & tax | 0.7 | 0.9 | 0.3 |
| Profit before tax | 0.7 | 0.9 | 0.3 |
| Net profit | 0.0 | 1.0 | 0.3 |
| Operating margin | 4.1% | 4.8% | 2.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +19.90% |
|---|
BSE results filing, NSE: SANDUPHQ. Figures extracted from the filing.
Sandu Pharmaceuticals Ltd: key numbers
- Share price
- ₹37.68
- Market cap
- ₹36.40 Cr
- Revenue (annual)
- ₹69.93 Cr
- Net profit (annual)
- ₹1.77 Cr
- P/E (TTM)
- 15.0×Sector 43.8×
- Promoter holding
- 37.79%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sandu Pharmaceuticals Ltd
All →Sandu Pharmaceuticals Board Meeting Date
Sandu Pharmaceuticals scheduled a board meeting on November 14, 2026, to approve unaudited financial results. The meeting covers the quarter and half-year ended September 30, 2026.
Sandu Pharmaceuticals Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals intimated that Non-Executive Independent Director Dr Neeti Madan Kapre has changed her name to Dr Neeti Gupta after marriage. The DIN, designation and directorship remain unchanged.
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals Limited has issued a reminder to physical shareholders regarding the mandatory submission of PAN and KYC details. This compliance follow-up aims to facilitate electronic dividend payments.
Sandu Pharmaceuticals Management Change
Sandu Pharmaceuticals appointed Dr. Neeti Madan Kapre as director and Dave & Dave as statutory auditor, while announcing other board and auditor tenure changes.
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals has appointed M/s. Dave & Dave as Statutory Auditors for a five-year term, following the tenure expiry of the previous auditors.